
Raquel LÃ³pez-MejÃ-as

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7443261/publications.pdf Version: 2024-02-01



RAQUEL LÃ3DEZ-MELÃAS

#	Article	IF	CITATIONS
1	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. Rheumatology, 2022, 61, 1204-1210.	0.9	7
2	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	16
3	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. Biomedicines, 2022, 10, 851.	1.4	3
4	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.4	0
5	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	0.8	8
6	Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease. Biomedicines, 2021, 9, 458.	1.4	3
7	Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. Arthritis Research and Therapy, 2021, 23, 111.	1.6	7
8	<i>HLA–B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 963-969.	2.9	12
9	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Scientific Reports, 2021, 11, 11510.	1.6	5
10	Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. Biomedicines, 2021, 9, 847.	1.4	10
11	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Scientific Reports, 2021, 11, 16163.	1.6	1
12	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Scientific Reports, 2021, 11, 22574.	1.6	4
13	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
14	The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39, 21-26.	0.4	13
15	Effect of cardiovascular disease on chronic inflammatory joint disease: reverse causality?. Expert Review of Clinical Immunology, 2020, 16, 855-858.	1.3	0
16	Endothelial Progenitor Cells as a Potential Biomarker in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 4098.	1.0	16
17	Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis. Scientific Reports, 2020, 10, 9636.	1.6	13
18	A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis. Scientific Reports, 2020, 10, 3355.	1.6	20

RAQUEL LÃ³PEZ-MEJÃAS

#	Article	IF	CITATIONS
19	Influence of MUC5B gene on antisynthetase syndrome. Scientific Reports, 2020, 10, 1415.	1.6	12
20	Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 917-924.	0.4	2
21	The role of a functional variant of TYK2 in vasculitides and infections. Clinical and Experimental Rheumatology, 2020, 38, 949-955.	0.4	2
22	Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 166-170.	0.4	0
23	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 182-187.	0.4	0
24	IL-6: linking chronic inflammation and vascular calcification. Nature Reviews Rheumatology, 2019, 15, 457-459.	3.5	42
25	SAT0124â€MOLECULAR CHARACTERIZATION OF THE SERUM PROFILE ASSOCIATED TO THE INCREASED CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. EFFECTS OF BIOLOGICAL DRUGS , 2019, , .		0
26	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
27	Identification of a 3′â€Untranslated Genetic Variant of <i><scp>RARB</scp></i> Associated With Carotid Intimaâ€Media Thickness in Rheumatoid Arthritis: A Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2019, 71, 351-360.	2.9	26
28	Relationship Between Insulin Sensitivity and β-Cell Secretion in Nondiabetic Subjects with Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 229-236.	1.0	10
29	Implication of CXCL5 (epithelial neutrophil-activating peptide 78) in the development of insulin resistance in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 373-379.	0.4	2
30	Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 465-473.	0.4	19
31	IgA Vasculitis: Genetics and Clinical and Therapeutic Management. Current Rheumatology Reports, 2018, 20, 24.	2.1	44
32	Cross-phenotype analysis of Immunochip data identifies <i>KDM4C</i> as a relevant <i>locus</i> for the development of systemic vasculitis. Annals of the Rheumatic Diseases, 2018, 77, 589-595.	0.5	27
33	Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review. Autoimmunity Reviews, 2018, 17, 301-315.	2.5	72
34	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Seminars in Arthritis and Rheumatism, 2018, 48, 22-27.	1.6	123
35	Association of circulating calprotectin with lipid profile in axial spondyloarthritis. Scientific Reports, 2018, 8, 13728.	1.6	12
36	Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa. PLoS ONE, 2018, 13, e0190568.	1.1	9

#	Article	IF	CITATIONS
37	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.4	30
38	Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients. Clinical and Experimental Rheumatology, 2018, 36, 302-309.	0.4	5
39	Amylin in the insulin resistance of patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36, 421-427.	0.4	2
40	High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein. Journal of Clinical Lipidology, 2017, 11, 1043-1054.e2.	0.6	35
41	Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis. Scientific Reports, 2017, 7, 10525.	1.6	14
42	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. Scientific Reports, 2017, 7, 5088.	1.6	44
43	Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus. Thrombosis and Haemostasis, 2017, 117, 2194-2206.	1.8	29
44	Incretins in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 229.	1.6	12
45	Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. Clinical and Experimental Rheumatology, 2017, 35, 885-892.	0.4	14
46	Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy. Journal of Osteoporosis, 2016, 2016, 1-6.	0.1	13
47	Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderateâ€ŧoâ€severe psoriasis undergoing antiâ€ŧumor necrosis factorâ€Î± therapy. Journal of Dermatology, 2016, 43, 389-394.	0.6	11
48	Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. Scientific Reports, 2016, 6, 29713.	1.6	34
49	Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis. Clinical Science, 2016, 130, 1889-1899.	1.8	16
50	Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti–Highâ€Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease. Arthritis and Rheumatology, 2016, 68, 1367-1376.	2.9	29
51	Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). Journal of the American Academy of Dermatology, 2016, 75, 329-335.	0.6	45
52	Antiâ€ŧumor necrosis factorâ€alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6â€month prospective study. Journal of Dermatology, 2016, 43, 1267-1272.	0.6	51
53	Gene polymorphisms and therapy in rheumatoid arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 225-229.	1.5	7
54	Decreased expression of methylene tetrahydrofolate reductase (MTHFR) gene in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 106-10.	0.4	26

Raquel LÃ³pez-MejÃas

#	Article	lF	CITATIONS
55	Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 1013-1019.	0.4	9
56	Lack of Association between <i>JAK3</i> Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis. BioMed Research International, 2015, 2015, 1-11.	0.9	9
57	Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Research and Therapy, 2015, 17, 102.	1.6	33
58	Brief Report: Association of HLA–DRB1*01 With IgA Vasculitis (Henochâ€Schönlein). Arthritis and Rheumatology, 2015, 67, 823-827.	2.9	35
59	Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. Rheumatology International, 2015, 35, 2069-2078.	1.5	25
60	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-SchĶnlein purpura (IgA vasculitis). Arthritis Research and Therapy, 2015, 17, 286.	1.6	11
61	Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 39-45.	1.0	26
62	Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 241-9.	0.4	6
63	TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 491-7.	0.4	6
64	Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis. BioMed Research International, 2014, 2014, 1-11.	0.9	33
65	Lack of association between IL6 gene and Henoch-Schönlein purpura. Clinical and Experimental Rheumatology, 2014, 32, S141-2.	0.4	8
66	Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2013, 31, 761-6.	0.4	18
67	The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, R42.	1.6	12
68	Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Atherosclerosis, 2011, 219, 655-658.	0.4	21
69	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 0, , .	0.4	1
70	lrisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. Frontiers in Immunology, 0, 13, .	2.2	9